The GI imaging platform called IMGINA Endoscopy System developed by PENTAX, having received FDA clearance will soon be releasing in the United States.
Two powerful and long lasting LEDs are sported by the new endoscope at its tip, and the good news is that regular replacement is not demanded by them. This will save cost, as traditionally having to swap bulbs was a costly affair due to the expensive bulbs. Thus if enough procedures are given, the new bulbs will help the clinics save cost over the old ones. A touch screen display on the control unit with 1080p resolution and HD+ CMOS light sensor are also featured in the newly developed system.
Tissue tecture, blood vessels and targets of interest can clearly be viewed thanks to a combination of high end illumination with high resolution imaging. In a PENTAX press release, Centre for Gastrointestinal Endoscopy, Prague, Czech Republic; Dr. Stepan Suchnaek shared his thoughts about the new system saying that the device is not just an upgrade to the existing systems; instead it is something entirely a new concept in the field of endoscopy. Being an attractive cost model, it features new technology that delivers superior visualization as well. He concluded by saying that effective and efficient cost effective treatment can be expected from the new device, which is a good news for the health system over all.
According to the president and CEO of PENTAX Medical, Americas; David Woods, the ASC market today is underserved. In order to stay within the budget, these practices are often limited to used or previous- generation equipment. The core GI market needs will be better served with the launch of the IMAGINA. Most, importantly, without having to compromise on the required standard of care, maximum cost predictability is assured by the system.
Dr.James Robinson, MD, MS is an Associate Professor of Epidemiology and Medicine DescriptionThe Icahn School of Medicine at Mount Sinai is a private graduate medical school in Manhattan, New York City, where he serves as a founding co-Director of the Center for Drug Safety and Effectiveness. He is a practising general internist and pharmacoepidemiologist and is internationally recognised for his research examining prescription drug utilisation. Dr.James Robinson is the author of over a hundred scientific articles and book chapters, is a frequent speaker on health care issues and has served on numerous editorial and advisory boards.
Email Id: email@example.com